Albuterol sulfate (Proventil HFA) vs Salbutamol HFA-152a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Albuterol sulfate (Proventil HFA)
Marketed by Kindeva Drug Delivery and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 471 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs) During Run-in Period" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: April 2027 · NCT06433921 (registry estimate)
Reported efficacy
Number of participants with Adverse Events (AEs) (Up to 3 months): Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). (not_applicable)
Result source: NCT06261957
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Albuterol sulfate (Proventil HFA) | Salbutamol HFA-152a |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00667407 | —Not reported |
| Trough FEV1, change | —Not posted · NCT00667407 | —Not reported |
| ACQ-5, change | —Not posted · NCT00667407 | —Not reported |
| OCS dose reduction | —Not posted · NCT00667407 | —Not reported |
Severe exacerbations, annualised rate
- Albuterol sulfate (Proventil HFA)
- —Not posted · NCT00667407
- Salbutamol HFA-152a
- —Not reported
Trough FEV1, change
- Albuterol sulfate (Proventil HFA)
- —Not posted · NCT00667407
- Salbutamol HFA-152a
- —Not reported
ACQ-5, change
- Albuterol sulfate (Proventil HFA)
- —Not posted · NCT00667407
- Salbutamol HFA-152a
- —Not reported
OCS dose reduction
- Albuterol sulfate (Proventil HFA)
- —Not posted · NCT00667407
- Salbutamol HFA-152a
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Albuterol sulfate (Proventil HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Albuterol sulfate (Proventil HFA): 0 of 4 rows · Salbutamol HFA-152a: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Salbutamol HFA-152a |
|---|---|
| Dropout rate | —800 uga NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result—200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —800 uga NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result—200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%800 uga NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result3.3%200 ug NCT06433908 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 800 uga catheter site related reaction 30% headache 16.7% cough 10% NCT06433908 · Phase 1 · registry result, not featured evidence show 1 more result200 ug catheter site haematoma 16.7% headache 10% abdominal pain 6.7% NCT06433908 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuterol sulfate (Proventil HFA)'s landscape · Salbutamol HFA-152a's landscape